DGX

Quest Diagnostics operates the largest clinical lab network in America, processing 150 million tests annually across 2,200 patient service centers and partnerships with 7,000 hospitals. The company's scale advantage creates a defensive moat through route density economics and direct payer relationships that smaller labs can't replicate. Management expects 4-6% organic revenue growth driven by an aging population requiring 3-4% more lab tests per year, plus continued market share gains from hospital outsourcing trends. Trading at 16.9x forward earnings with 14.5% ROE, DGX offers steady cash generation in a recession-resistant business that thrived during COVID disruptions. The stock yields 1.8% with consistent buybacks reducing share count by 2-3% annually.